Stifel raises Supernus Pharmaceuticals stock price target to $50 on strong Q3
PositiveFinancial Markets

Stifel raises Supernus Pharmaceuticals stock price target to $50 on strong Q3
Stifel has raised its price target for Supernus Pharmaceuticals to $50 following a strong performance in the third quarter. This adjustment reflects confidence in the company's growth and potential, which is significant for investors looking for promising opportunities in the pharmaceutical sector.
— via World Pulse Now AI Editorial System





